Educational use only
This page does not recommend Pinealon for memory, dementia, sleep, mood, performance, or neurodegenerative disease. Neurologic symptoms require qualified medical care.
Identity snapshot
| Common names | Pinealon, EDR peptide |
|---|---|
| Sequence | EDR - Glu-Asp-Arg |
| Type | Synthetic tripeptide |
| Stated target in Khavinson table | Brain functions |
| Main search cluster | Neuroprotection, cognition, Alzheimer's disease mechanism papers |
Evidence map
The EDR literature includes mechanism reviews and experimental models focused on neuronal function, apoptosis markers, antioxidant pathways, dendritic spines, and gene/protein expression in the context of neurodegenerative-disease hypotheses. That makes Pinealon a useful literature-mapping term, but not a proven cognitive treatment.
The PubMed-indexed 2020 Molecules review on EDR discusses possible mechanisms in Alzheimer's disease pathogenesis. A mechanism review can generate hypotheses and organize prior work; it does not establish that a commercial Pinealon product prevents or treats Alzheimer's disease.
Common confusions
- Pinealon is EDR, not AEDG.
Epitalon is AEDG and belongs to the pineal/neuroendocrine search cluster. - Pinealon is not a broad pineal extract.
It is a defined short sequence; natural complex products use different names. - Brain target does not equal brain treatment.
A stated tissue context is not equivalent to clinical proof for neurologic disease. - Vendor summaries often overstate certainty.
Use primary papers and source hierarchy before accepting protocol claims.
Pinealon memory benefits from studies, dosage from studies, and side effects
Common Pinealon searches ask for memory benefits, nootropic use, Pinealon dosage, side effects, FDA status, and legal status. This page captures those terms directly, but answers them from the academic literature: what dose or exposure was reported, what endpoint was measured, and what cannot be concluded.
| Source context | Study-only dose or exposure | Reported benefit endpoint | Interpretation limit |
|---|---|---|---|
| 2021 Molecules EDR review | Reports oral Pinealon/EDR administration with standard therapy in 72 patients; the accessible review text does not state a dose amount. | Memory, headache duration/intensity, emotional balance, and performance-efficacy endpoints after traumatic brain injury consequences and cerebrasthenia. | Reported through secondary regional literature inside a review, not a standalone modern dosing guideline. |
| EDR mechanism studies summarized in the review | Cell and animal exposure details vary by cited experiment; this page does not convert them to human dosage. | ROS, MAPK/ERK timing, neuronal apoptosis, dendritic-spine preservation, and antioxidant-system markers. | Mechanism endpoints are not the same as proven nootropic benefits. |
| 2014 Khavinson short-peptide table | No consumer dose; identifies Pinealon as EDR - Glu-Asp-Arg. | Brain-function activity category. | Identity and tissue-target mapping, not legal or medical-use guidance. |
Pinealon side effects: known vs unknown
The side-effect profile of a real-world product cannot be inferred from the letters EDR. The reviewed sources do not establish a reliable adverse-event rate, contraindication list, interaction profile, or route-specific risk profile for consumer Pinealon products. Product identity, route, purity, labeling, and patient context matter. Neurologic or cognitive symptoms should not be self-managed with research-peptide information.
FDA status and legal status
Pinealon FDA status and Pinealon legal status searches need a jurisdiction-specific answer. This page does not identify an FDA-approved Pinealon drug in the United States as of the May 5, 2026 review. FDA says consumers can check Drugs@FDA and the Orange Book for approved drug products; those are better legal-status starting points than vendor pages. Compounded drugs are not FDA-approved, and research-use or supplement-style labels do not by themselves establish safety, effectiveness, quality, or lawful human-use marketing. Product identity, purity, route, stability, and adverse-event reporting remain practical unknowns.
Sources
- Khavinson, "Peptides, Genome, Aging" (2014) - EDR/Pinealon table entry.
- EDR peptide mechanism review, Molecules 2020.
- PubMed record for EDR/Pinealon review.
- FDA: how to check whether a drug is approved - legal-status verification context.
- FDA compounding Q&A - U.S. safety and approval context.
- MedlinePlus: Evaluating Health Information - source-quality framework.